We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Watch Our Video

Read the Latest

CRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

Alan Krasner, M.D., chief medical officer at Crinetics, added, “We are very encouraged by these single ascending dose data that clearly demonstrate proof-of-SST5 agonism and resultant inhibition of insulin secretion with CRN04777 exposure in healthy volunteers. We are excited by the possibility that CRN04777 may serve as an oral treatment to normalize glucose levels in any child born with congenital HI regardless of their specific genetic mutation and eagerly look forward to better understanding its full potential with additional clinical studies.”

Crinetics Pharmaceuticals to Participate in September Investor Conferences

Crinetics' management will be participating in investor conferences hosted by H.C. Wainwright, SVB Leerink and Cantor Fitzgerald during the month of September.